U.S. markets closed

Inovio Pharmaceuticals, Inc. (GBMB.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
3.5920-0.1870 (-4.95%)
At close: 04:30PM CET
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.7790
Bid3.4965 x 30000
Ask3.5300 x 30000
Day's Range3.5655 - 3.5920
52 Week Range3.5655 - 16.4000
Avg. Volume923
Market Cap755.706M
Beta (5Y Monthly)0.49
PE Ratio (TTM)N/A
EPS (TTM)-0.9810
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.22
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for GBMB.F

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Zacks

      Down 21.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO)

      The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

    • Motley Fool

      Better Vaccine Stock: Ocugen vs. Inovio Pharmaceuticals

      Ocugen jumped into the race to develop a vaccine for COVID-19 by partnering up with Bharat Biotech, an India-based biotech company. Bharat Biotech ran a late-stage clinical trial for the vaccine in question, Covaxin, in India, and earned emergency use authorization (EUA) for it there.

    • TipRanks

      Is 15% Potential Upside Good Enough to Risk Buying Inovio Stock? Analyst Weighs In

      Compared to peers in the vaccine space, Inovio Pharmaceuticals’ (INO) DNA-based platform is somewhat unique. It could potentially boast the same hallmarks as mRNA vaccines – such as rapid modification, easy scale-up, no anti-vector immunity – but might also provide an improved safety and tolerability profile. And for that reason, Jefferies’ Roger Song thinks it the has the potential for “long-term value through a diverse pipeline.” This pipeline includes more than 15 different prophylactic/thera